Cite
Supplementary figure 1 legend from Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
MLA
Christopher G. Wood, et al. Supplementary Figure 1 Legend from Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....230aa1b58f11e52fbe380d1b2d235b7b&authtype=sso&custid=ns315887.
APA
Christopher G. Wood, Charles A. Nicolette, Irina Y. Tcherepanova, Joe Horvatinovich, Marcus S. Norris, Ana Plachco, Alicia Gamble, Mark DeBenedette, Gennady Bratslavsky, William Lowrance, Daniel Vaena, Anil Kapoor, Viraj Master, David Y.T. Chen, Scott S. Tykodi, Robert G. Uzzo, Nizar M. Tannir, & Robert A. Figlin. (2023). Supplementary figure 1 legend from Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Chicago
Christopher G. Wood, Charles A. Nicolette, Irina Y. Tcherepanova, Joe Horvatinovich, Marcus S. Norris, Ana Plachco, Alicia Gamble, et al. 2023. “Supplementary Figure 1 Legend from Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....230aa1b58f11e52fbe380d1b2d235b7b&authtype=sso&custid=ns315887.